Intravitreal bevacizumab in a patient with neovascular glaucoma

Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):144-6.


The utility of intravitreal bevacizumab injection in a patient with neovascular glaucoma following central retinal vein occlusion is explored. Bevacizumab (1 mg in 0.04 mL) was used after failed intraocular pressure (IOP) control with transscleral cyclophotocoagulation and panretinal photocoagulation. IOP improved within 2 days and the patient experienced marked improvement in comfort. Bevacizumab may be an effective medication for the treatment of neovascular glaucoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Follow-Up Studies
  • Glaucoma, Neovascular / drug therapy*
  • Glaucoma, Neovascular / etiology
  • Humans
  • Injections
  • Intraocular Pressure / drug effects
  • Iris / blood supply
  • Neovascularization, Pathologic / complications
  • Vascular Endothelial Growth Factor A / immunology
  • Vitreous Body


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab